ELTP News Alert Elite Pharma Inc (ELTP) 0.2260 01/01/2015 15

New Post Public Reply Private Reply Replies (0) Message Board

Jan 1, 2015 at 4:08 PM

Elite Pharma Inc (ELTP) 0.2260 $ELTP

Elite Pharmaceuticals receives second abuse deterrent drug formulation patent in Canada
M2 - Wed Dec 17, 8:09AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) announced on Tuesday that it has received the second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof" to expand the scope and reach of its patent estate internationally.

Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
GlobeNewswire - Tue Dec 16, 7:38AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property protection covering the Company's abuse deterrent technology with the issuance of a second Canadian Patent, Number 2,541,371, entitled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance continues to expand the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
GlobeNewswire - Wed Dec 03, 8:56AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for ELI-201, Elite's twice daily abuse-deterrent oxycodone product which utilizes Elite's proprietary pharmacological abuse-deterrent technology.

Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 19, 4:49PM CST

Elite Pharmaceuticals achieves 8% increase in revenues for Q2 fiscal 2015
M2 - Wed Nov 19, 6:15AM CST
Specialist pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Tuesday that its consolidated revenues was USD1.3m for the second quarter of fiscal year 2015 ended 30 September 2014.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Tue Nov 18, 5:24PM CST
Revenues increase by 8%

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
GlobeNewswire - Thu Nov 13, 4:02PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that management will host a conference call to provide a quarterly business update on Wednesday, November 19, 2014 at 11:00 AM EST. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals Announces New Management Appointments
GlobeNewswire - Fri Oct 24, 6:15AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP),a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Kenneth Smith, J.D., M.B.A., as Vice President of Legal, Dr. Jason LePree as Vice President of Scientific Affairs and Dr. Sophy Abraham as Head of Regulatory Affairs.

Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
GlobeNewswire - Tue Sep 09, 6:04AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
GlobeNewswire - Wed Sep 03, 12:47PM CDT
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with niche generic products, today announced that Nasrat Hakim, Elite's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Healthcare Conference on Tuesday, September 9, 2014 at 2:55 PM Eastern Time. The conference is being held at The New York Palace Hotel in New York City.

OTC Daily Trading News: Evoq Properties, Inc. MedBox, Inc. LabStyle Innovations Corp, MyEcheck, Inc. Elite Pharmaceuticals, Inc.
PR Newswire Europe - Tue Aug 19, 10:11AM CDT
LONDON, August 19, 2014 /PRNewswire/ --

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
GlobeNewswire - Thu Aug 14, 3:14PM CDT
Revenues Increase by 61%, Product Development on Schedule

Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014
GlobeNewswire - Wed Aug 13, 6:09AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced today that management will host a conference call to provide a quarterly business update at 11:00 AM ET on Monday, August 18, 2014. Company executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals reports launch of pivotal bioequivalence study of ELI-201 in healthy volunteers to address issues in prescription drug abuse
M2 - Wed Jul 16, 9:08AM CDT
Controlled release drug products company Elite Pharmaceuticals (OTC BB:ELTP) disclosed on Tuesday the dosing of the first volunteer in a pivotal bioequivalence study of ELI-201 utilising its proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
GlobeNewswire - Tue Jul 15, 10:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

(OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201, the Company's twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology.

Elite Pharmaceuticals posts higher consolidated revenues of USD4.6m for fiscal 2014
M2 - Tue Jul 01, 2:53AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTC BB:ELTP) stated on Monday its consolidated revenues of USD4.6m for the fiscal year ended 31 March 2014 (fiscal 2014).

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
GlobeNewswire - Mon Jun 30, 1:05PM CDT
Revenues Increase by 35%, Product Development Accelerating

Elite Pharmaceuticals, Inc. to Host 2014 Fiscal Year End Conference Call on Tuesday, July 1, 2014
GlobeNewswire - Thu Jun 26, 9:56AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Platform Revolutionizes Campus Career Services

Reinventing the Campus Job Connection Technological tides are sweeping through universities like a gale force wind, shaking up the job-seeker game for students. Rollie Jobs is at the helm of this tech evolution, flexing its AI-powered muscles to revamp how career services function. The brainy folks behind Rollie Jobs are crafting a smoother bridge between textbooks and...

Berney Flowers Rings the Bell on Fiscal Reform

Berney Flowers: A Voice for Fiscal Change Oh boy, Berney Flowers sure isn't holding back. The Maryland congressional candidate is out here on Biz Talk Today TV, aiming straight at the heart of government waste and promising fiscal reform with the kind of intensity you don't see every day. Through the airwaves, he's been championing independent audits to keep those...

b.well and MyDirectives Streamline Access to Care Plans

Pioneering Access to Critical Care Documents Ever thought about where all those critical healthcare documents are stashed? Trust me, it’s often a mess—file cabinets, bookshelves, or stuck in some forgotten safety deposit box. Well, b.well Connected Health and MyDirectives are rolling up their sleeves to change that. They've teamed up to make advance care planning...

NAPCO Security's Innovative Push at ISC East 2026

NAPCO's New Showcase at ISC East 2026 Let's dive into NAPCO Security Technologies' latest development, because these folks are taking the stage at the ISC East 2026, one of the big kahunas in security trade shows. Happening on November 4th and 5th at the Jacob Javits Center, the booth near the main entrance will be the place to catch the latest from this New York outfit,...

Radware Dominates SPARK Matrix™ for Bot Management

Why Radware Stands Out in Bot Management Radware has been making quite the splash in the tech world, now sitting pretty as the leader in QKS Group's SPARK Matrix™ for Bot Management in 2026. This isn't just some random pat on the back; it's a recognition of Radware's outstanding execution. Their innovative approach, especially in the realm of cloud application...

Kenneth Spells: Championing Education Leadership in 2026

Out there in Hoke County, you’ve got a man named Kenneth Spells shaking things up the way a strong leader should. Now, you know I’m not here to fluff up anyone’s feathers—especially in an arena as aching for reform as education. But credit where credit’s due, Spells picked up the ‘2026 Professional of the Year’ from The Inner Circle for a reason, and it’s...

qBraid OS Launching Quantum Computing to New Heights

Paving a New Era for Quantum Computing That quantum computing isn't just about flashy algorithms anymore. It's about weaving together some downright powerful hardware under a seamless system. Enter qBraid OS, the new kid on the block offering a sprawling interface to drape quantum processors, CPUs, and NVIDIA GPUs over one cohesive operating system. Folks in the thick of...

St. Croix Financial Hub: Game Changer or Fluff?

You know, sometimes it feels like the financial world gets more tangled than a fishing line on a windy beach. This latest spiel coming out of St. Croix with all its big names and lofty promises—Governor Bryan’s 3rd Wall Street Financial District Hub Initiative—seems like one of those, but maybe it’s got more meat than hype. Half the pitch sounds like your typical...

HYPOTHESIS Blends Style and Function in Health Gear

Pushing the Limits with HYPERX Knit Look, healthcare workers ain't just clocking in and out—they're on their feet all day, twisting, reaching, and moving. So when HYPOTHESIS tossed this shin-dig in Los Angeles for their HYPERX knit collection, it wasn't just to show off some snazzy scrubs. It was about bridging a gap: wellness meets grind. You reckon a pair of old...

AST SpaceMobile Faces Class Action Amid Investor Concerns

AST SpaceMobile: Trouble in the Cosmic Neighborhood AST SpaceMobile's recent legal scuffle signals a wake-up call. Investors, brace yourselves; the company is staring down the barrel of a class-action lawsuit. This ain’t your quiet Sunday read—it’s a full-blown securities firefight. When the DJS Law Group throws down the gauntlet, you know it's serious business....